Clinico-Epidemiological Characteristics of Pediatric COVID-19 Patients in Bangladesh

Probir Kumar Sarkar  
Dhaka Shishu (Children) Hospital

Kinkar Ghosh  
Dhaka Shishu (Children) Hospital

Dr Reaz Mobarak  
Dhaka Shishu (Children) Hospital

Md Kamruzzaman  
Dhaka Shishu (Children) Hospital

Rizwanul Ahsan  
Dhaka shishu (Children) Hospital

Dr Shireen Afroz  
Dhaka Shishu (Children) Hospital

Maksudur Rahman  
Dhaka Shishu (Children) Hospital

Nabila Akand  
Dhaka Shishu (Children) Hospital

Nahid Farzana  
Dhaka Shishu (Children) Hospital

Shah Ali Akbar Ashrafi  
Dhaka Shishu (Children) Hospital

Maleeha Sheefa  
World Health Organization: Bangladesh Office

Nurun Nahar  
Dhaka Shishu (Children) Hospital

Dr Syed Shafi Ahmed  
Dhaka Shishu (Children) Hospital

Sheikh Wasik Rahman  
Child Health Research Foundation

Anjim Macsud  
Pi Research Consultancy Center

Mohammad Jahid Hasan  
( dr.jahid61@gmail.com )  
Pi Research Consultancy Center  https://orcid.org/0000-0001-9212-1739

Research Article
Abstract

Background

To delineate the clinico-epidemiological characteristics of pediatric coronavirus disease-2019 (COVID-19) patients was the objective of the study.

Method:

This observational study included 290 pediatric patients with a definite diagnosis of COVID-19 admitted to Dhaka Shishu Hospital, Bangladesh, from April 2021 to October 2021. Clinical and epidemiological characteristics were analyzed based on demographic data, medical history, laboratory tests, and outcome information. Data analysis was performed with SPSS 26. Ethical measures were taken in compliance with the current declaration of Helsinki, and final analysis was performed using SPSS 26.

Result

Of all, 42 (14.5%) were neonates (<28 days), 88 (30.3%) were infants (28 days to <1 year) and 160 (55.2%) were children (1–17 years). The median age of the children was 18 (0.3–204) months, 58.3% were male, 62% had malnutrition, and presented with various clinical presentations. The main symptoms were fever (5.7%) and breathlessness (20%). Approximately 22% of children were asymptomatic, and 57% had at least one comorbidity. Fever and abdominal pain were predominant presenting symptoms in children compared with neonates and infants (p < .01 for both), while cough and breathlessness were more frequent in infants (p < .01 for both). The infants suffered significantly from neutropenia and lymphocytosis than neonates and children (p < .001 for both). The discharge and death rates were 77.8% with 6.9%. Overall case fatality was higher among neonates than others.

Conclusion

Compared to other pediatric groups, neonatal case fatality was higher, and COVID-19 in neonates, infants, and children has similar epidemiological and clinical manifestations. The findings from this study might help to guide the development of measures to prevent and treat this ongoing global pandemic of these particular age groups.

1. Background:

Since December 2019, an outbreak of undiagnosed pneumonia cases with presumptive viral origin started in Wuhan, China, and began to spread rapidly throughout the world [1]. At the beginning of 2020, the International Committee on Taxonomy of Viruses denominated this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2]. The World Health Organization (WHO) designates this pandemic disease as coronavirus disease 2019 (COVID-19) [2–4] and later declares a public health emergency of international concern [5]. To date, over 140 million patients have been diagnosed with COVID-19 globally [6]. The cumulative number of
laboratory-confirmed cases has been reported to be over 700,000, and more than 10,000 reported deaths [7]. The clinical spectrum of COVID-19 is wide, varying from completely asymptomatic forms to those characterized by severe respiratory distress requiring intensive care resulting in death [8–10]. All ages are susceptible to this infection. However, the number of confirmed cases in children with COVID-19 is relatively small; hence, very limited information is available compared to adults [11, 12]. One of the largest surveys revealed that 2.2% [13] of children were affected in China, while in the USA, the number was 1.7% [14]. The exact prevalence of COVID-19 among Bangladeshi children is still lacking.

Ample evidence suggests that compared to adults, children with COVID-19 have distinct epidemiological and clinical manifestations [15]. For example, when adult patients predominantly present with fever, cough, breathlessness, sore throat, and headache, children present with cough, pharyngitis, fever, diarrhea, vomiting, and a negligible amount of gustatory and olfactory symptoms [16–18]. In addition, there are fewer severe cases than adults [17, 19, 20]. Most likely, therefore, very limited comprehensive guidelines are available focusing on the management of COVID-19 in children rather than adults [16]. However, understanding the clinical manifestation of the pediatric population and their variation in different age groups, including neonates (< 28 days), infants (28 days to < 1 year), and children (1 year to < 18 years), is important for clinical and containment strategies. Considering the lack of detailed epidemiological information of pediatric patients, we conducted an observational study to record epidemiological and clinical features and outcome data up to discharge among the different pediatric populations (neonates, infants, and children < 18 years) admitted to Dhaka Shishu Hospital, Bangladesh.

2. Methods;

2.1 Study design and participants:

This observational study was approved by the institutional review board (IRB) of Dhaka Shishu Hospital (DSH), Dhaka, Bangladesh [ethical approval no. 651(1)/DSH/2020)]. Children admitted to the hospital with clinical features consistent with COVID-19 were initially quarantined prior to SARS-CoV-2 nucleic acid detection [21]. Bed-sided nasopharyngeal swab of suspected patients was collected using a swab stick by a skilled health care worker for RT-PCR. Suspected COVID-19 cases were defined as the presence of at least one clinical manifestation: fever, breathlessness, tachypnea, lethargy, poor feeding, cough, vomiting, diarrhea, sore throat, or runny nose during admission. A reverse transcriptase-polymerase chain reaction (RT-PCR) test was performed for all suspected cases with the samples collected from the respiratory tract. Laboratory-confirmed [positive RT-PCR (qualitative) for SARS-CoV-2] cases were finally included within the period spanning from May 2020 to December 2020. Parents who did not provide consent to participate in the study refrained from inclusion. Assessment of the children and management was ensured according to the recommendation of the National Guidelines on Clinical Management of COVID-19 [22] and interim guidance provided by the Bangladesh Pediatric Association (BPA). Details of the patient selection are available in supplementary Fig. 1.

Data collection procedure:

A preformed questionnaire was prepared based on published literature and was piloted among 15 cases admitted to DSH. Experiences from the piloting were adjusted during the finalization of the questionnaire. The
medical records of the included patients were accessed by the study research physicians. Prior to data collection, all of the research physicians (a total number of four) were trained for data collection and clinical record assessment. Clinical data were extracted, including demographic data, clinical symptoms, signs, comorbidities, and laboratory findings. Nutritional assessments were also performed by a growth monitoring promotion (GMP) card. Mid upper arm circumference (MUAC) tape was used during the assessment of mid upper arm circumference (MUAC), and body weights of neonates and infants were measured with WS590 - Baby Weighing Scales. For children aged more than 1 year, a digital body weight measuring scale was used. All patients were managed by standard care for COVID-19. Comorbidities were also managed based on the diagnosis and treatment protocol of the disease. All patients were followed-up to the discharge. The outcome was defined as recovery, death, referred to the superspecialized center, and left the hospital against advice. The discharge criteria followed in the study were as follows: normal body temperature or no fever for at least three consecutive days; alleviation of upper respiratory symptoms (in comparison to the admission day); and negative RT-PCR (qualitative) results obtained for SARS-CoV-2 nucleic acid detection at day 14 (from the index test). Written informed consent was provided by their parents or guardians before data collection.

Quality assurance of the data and reporting guidelines

The principal investigator and/or his team supervised the data collection procedures and randomly cross-checked the collected data to ensure quality control. In case of any breach of the standard procedure observed, the investigator team communicated with the research physicians and attending doctors to maintain the standard care and data collection process. After completion of the data collection, all data were sorted and stratified into three groups based on the age difference. Here, neonates were considered age less than 28 days, infants less than 1 year, and children between 1 year and < 18 years of age.

Statistical analyses:

Statistical analyses were conducted using SPSS software (version 26, IBM statistics). Missing values were managed by subtracting the data from the final data set. No mean imputation was made. Continuous data are expressed as the mean ± standard deviation or median (range), while categorical data are presented as a number, frequency, or percentage. Both parametric and nonparametric tests were used whenever necessary. The results are expressed with 95% confidence intervals (CIs), and a p-value < .05 was considered statistically significant.

3. Results:

A total of 290 pediatric patients with COVID-19 were included in the study. The median age of the patients was 18 months, with a range between 1 day and 17 years. Of all, 42 (14.5%) were neonates, 88 (30.3%) were infants and 160 (55.2%) were children. More than half of the pediatric patients were male (58.3%). Among all 73 (45.3%), 26 (16.1%) and 1 (0.6%) had severe malnutrition, moderate malnutrition and overnutrition, respectively. Nearly half of the pediatric patients (n = 146, 50.3%) had at least one comorbidity, and 20 (6.9%) had more than one comorbidity. Single comorbidities were significantly more common among children than neonates and infants, while more than one comorbidity was significantly more common among neonates (p < 0.001) (Table 1). A detailed list of comorbidities found among the pediatric patients is presented in supplementary
Acute leukemia and nephrotic syndrome were the comorbidities found in a significantly higher proportion in children (p < 0.05).

| Variable                           | Total n (%) | Neonate n (%) | Infant n (%) | Children n (%) | p-value  |
|------------------------------------|-------------|---------------|--------------|----------------|----------|
| Number                             | 290         | 42 (14.5)     | 88 (30.3)    | 160 (55.2)     |          |
| Age (months)                       |             |               |              |                |          |
| Median                             | 18 (0.3–204)| 0.25 (0.03–0.87) | 6 (0.97-12.00) | 64 (13–204)    |          |
| Sex                                |             |               |              |                |          |
| Male                               | 169 (58.3)  | 27 (64.3)     | 53 (60.2)    | 89 (55.6)      | 0.542    |
| Female                             | 121 (41.7)  | 15 (35.7)     | 35 (39.8)    | 71 (44.4)      |          |
| Weight (kg)                        |             |               |              |                |          |
| Mean ± SD                          | 7.61 ± 4.63 | 2.84 ± 0.49   | 5.73 ± 2.07  | 12.28 ± 3.67   |          |
| Nutritional Status*                |             |               |              |                |          |
| Normal                             | 61 (37.9)   | 12 (35.3)     | 23 (33.3)    | 26 (44.8)      | 0.448    |
| Severe malnutrition                | 73 (45.3)   | 17 (50.0)     | 36 (52.2)    | 20 (34.5)      |          |
| Moderate malnutrition              | 26 (16.1)   | 5 (14.7)      | 10 (14.5)    | 11 (19.0)      |          |
| Overnutrition                      | 1 (0.6)     | 0             | 0            | 1 (1.7)        |          |
| Number of comorbidities            |             |               |              |                |          |
| One                                | 146 (50.3)  | 5 (11.9)      | 37 (42.0)    | 104 (65.0)     | <0.001   |
| More than one                      | 20 (6.9)    | 1 (24)        | 7 (8.0)      | 12 (7.5)       |          |
| None                               | 124 (42.8)  | 36 (85.7)     | 44 (50.0)    | 44 (27.5)      |          |

*p-value determined by Chi-square test

*Excluding 129 missing values

The common clinical presentation was fever (n = 150, 51.7%), followed by breathlessness (n = 58, 20.0%), abdominal pain (n = 48, 16.6%), cough (n = 42, 14.5%), seizure (n = 37, 12.8%), and vomiting (n = 36, 12.4%), among others. Fever, abdominal pain, vomiting, rash, and weakness were significantly more common among children (p < 0.05). Breathlessness, cough, seizure, and vomiting were significantly more common among infants (p < 0.05) (Table 2).
Table 2
Clinical presentation of pediatric patients with COVID-19 (n = 290)

| Variable       | Total n (%) | Neonate n (%) | Infant n (%) | Children n (%) | p-value |
|----------------|-------------|---------------|--------------|----------------|---------|
|                | (n = 290)   | (n = 42)      | (n = 88)     | (n = 160)      |         |
| Asymptomatic   | 65 (22.4)   | 35 (83.3)     | 13 (14.8)    | 17 (10.6)      | < 0.001 |
| Fever          | 150 (51.7)  | 5 (11.9)      | 47 (53.4)    | 98 (61.3)      | < 0.001 |
| Breathlessness | 58 (20.0)   | 4 (9.5)       | 33 (37.5)    | 21 (13.1)      | < 0.001 |
| Abdominal pain | 48 (16.6)   | 0             | 11 (12.5)    | 37 (23.1)      | 0.001   |
| Cough          | 42 (14.5)   | 1 (2.4)       | 22 (25.0)    | 19 (11.9)      | 0.001   |
| Seizure        | 37 (12.8)   | 3 (7.1)       | 15 (17.0)    | 19 (11.9)      | 0.268   |
| Vomiting       | 36 (12.4)   | 0             | 9 (10.2)     | 27 (16.9)      | 0.009   |
| Sepsis         | 17 (5.9)    | 5 (11.9)      | 7 (8.0)      | 5 (3.1)        | 0.059   |
| Oedema         | 16 (5.5)    | 1 (2.4)       | 4 (4.5)      | 11 (6.9)       | 0.487   |
| Loose motion   | 14 (4.8)    | 0             | 7 (8.0)      | 7 (4.4)        | 0.138   |
| Rash           | 13 (4.5)    | 0             | 1 (1.1)      | 12 (7.5)       | 0.023   |
| Seizure        | 12 (4.1)    | 0             | 5 (5.7)      | 7 (4.4)        | 0.321   |
| Feeding problem| 11 (3.8)    | 0             | 6 (6.8)      | 5 (3.1)        | 0.147   |
| Weakness       | 9 (3.1)     | 0             | 0            | 9 (5.6)        | 0.021   |
| Sore throat    | 3 (1.0)     | 0             | 0            | 3 (1.9)        | 0.722   |
| Runny nose     | 2 (0.7)     | 0             | 1 (1.1)      | 1 (0.6)        | 1.000   |
| Unconsciousness| 2 (0.7)     | 0             | 1 (1.1)      | 1 (0.6)        | 1.000   |
| Delayed Cry    | 2 (0.7)     | 2 (4.8)       | 0            | 0              | 0.021   |
| Local Swelling | 1 (0.3)     | 0             | 0            | 1 (0.6)        | 1.000   |

*p-value determined by Chi-square test

Table 3 describes the investigation profile of the pediatric patients with COVID-19. The average hemoglobin level was 10.95 ± 2.78 g/dl (SD), with a significantly higher level among neonates than infants and children (p < 0.001). The average hematocrit was 34.54 ± 9.72% (SD), with a significantly higher value in neonates than in infants and children (p < 0.001). The median WBC count was 11.20 x 103/mm3, ranging from 0.01 to 127.80 x 103/mm3, with children having a significantly lower WBC count than neonates and infants (p < 0.001). The percentage of neutrophils was significantly lower and lymphocytes was significantly higher among infants than among neonates and children (p < 0.001). The median platelet count among pediatric patients was 2.80 x 106/mm3, with a significantly higher median value among infants than neonates and children (p < 0.001). Serum creatinine was significantly higher among neonates than among infants and children (p = 0.002).
Table 3
Investigation profile of pediatric patients with COVID-19 (n = 290)

| Investigation         | Total        | Neonate       | Infant        | Children      | p-value |
|-----------------------|--------------|---------------|---------------|---------------|---------|
|                       | Mean ± SD    | Mean ± SD     | Mean ± SD     | Mean ± SD     |         |
| Hemoglobin (g/dl)     | 10.95 ± 2.78 | 14.64 ± 3.02  | 10.46 ± 1.75* | 10.28 ± 2.45* | < 0.001 |
| Hematocrit (%)        | 34.54 ± 9.72 | 46.71 ± 10.10 | 33.43 ± 6.77* | 32.07 ± 8.69* | < 0.001 |
| RBC (x 10^6/mm³)      | 4.23 ± 0.95  | 4.42 ± 0.90   | 4.19 ± 0.77   | 4.04 ± 1.03   | 0.087   |
| WBC (x 10^3/mm³)      | 11.20 (0.01–127.80) | 12.50 (3.80–37.10) | 12.30 (0.01–126.00) | 10.10 (1.10–127.80)* | 0.001   |
| Neutrophil (%)        | 53.00 (3.00–91.00) | 59.00 (17.00–89.00) | 38 (9.00–85.00)* | 54.50 (3.00–91.00)* | < 0.001 |
| Lymphocyte (%)        | 41.00 (6.00–95.00) | 31 (6.00–72.00) | 51.50 (10.00–84.00)* | 38.50 (7.00–95.00)* | < 0.001 |
| Monocyte (%)          | 5.00 (0–34.00) | 6 (0–13.00)  | 6 (0–12.00)   | 4.00 (0–34.00)* |
| Eosinophil (%)        | 1.00 (0–17.00) | 1.00 (0–7.00) | 1.00 (0–17.00) | 1.00 (0–16.00) |
| Platelet (x 10^9/mm³) | 2.80 (0.12–8.06) | 2.52 (0.24–6.76) | 3.70 (0.22–8.06)* | 2.57 (0.12–7.76)* | < 0.001 |
| Serum creatinine (mg/dl) | 0.49 (0.01–10.71) | 0.84 (0.33–5.11) | 0.42 (0.01–5.72)* | 0.50 (0.03–10.71)* | 0.002   |
| Sodium (mmol/l)       | 141.38 ± 5.59 | 142.56 ± 6.49 | 140.88 ± 5.11 | 141.279 ± 5.53 | 0.371   |
| Potassium (mmol/l)    | 4.52 ± 1.04  | 5.28 ± 1.29   | 4.83 ± 0.97   | 4.13 ± 0.77*  | < 0.001 |
| Chloride (mmol/l)     | 102.29 ± 12.25 | 101.73 ± 14.37 | 103.76 ± 8.29 | 101.70 ± 13.28 | 0.571   |

Data is expressed as mean ± SD or median (min-max).

P-value determined by ANOVA and Kruskal Wallis Test where appropriate. Post-hoc analysis was conducted using Bonferroni or Games-Howell test. p < 0.05 in relation to Neonate* and Infant†

Among 290 pediatric children, outcome data were available for 288. Out of 288 pediatric participants, 78% recovered, 11% were referred, 7% died and 4% left against advice (Fig. 1).

We compared the demographic, nutritional, comorbidity, and investigation profiles between pediatric patients with COVID-19 who died and those who recovered (Table 4). The number of deaths was significantly higher among neonates than among infants and children (p < 0.05). Death did not vary significantly with the sex, nutritional status, or comorbidity of the patients. On investigation, hemoglobin, WBC count, neutrophil percentage, serum creatinine, and serum potassium level were significantly higher among those who died than among those who recovered (p < 0.05). However, lymphocyte and monocyte percentages were significantly lower among patients who died than among those who recovered (p < 0.05).
Table 4
Outcome of pediatric patients with COVID-19 in relation different characteristics (n = 290)

| Variable                          | Dead         | Recovered    | p-value   |
|-----------------------------------|--------------|--------------|-----------|
| n (%)                             | Dead (8.2)   | Recovered (91.8) |           |
| **Age, n (%)**                    |              |              |           |
| Neonate                           | 8 (19.5)     | 33 (80.5)    | 0.023*    |
| Infant                            | 5 (7.0)      | 66 (93.0)    |           |
| Children                          | 7 (5.3)      | 125 (94.7)   |           |
| **Sex, n (%)**                    |              |              |           |
| Male                              | 12 (8.3)     | 132 (91.7)   | 0.926*    |
| Female                            | 8 (8.0)      | 92 (92.0)    |           |
| **Nutritional Status, n (%)**     |              |              |           |
| Normal                            | 1 (2.0)      | 49 (98.0)    | 0.247*    |
| Severe malnutrition               | 6 (9.7)      | 56 (90.3)    |           |
| Moderate malnutrition             | 1 (4.3)      | 22 (95.7)    |           |
| Overnutrition                     | 0            | 1 (100.0)    |           |
| **Number of comorbidities, n (%)**|              |              |           |
| One                               | 7 (5.7)      | 115 (94.3)   | 0.176*    |
| More than one                     | 3 (16.7)     | 15 (83.3)    |           |
| None                              | 10 (9.6)     | 94 (90.4)    |           |
| **Investigation**                 |              |              |           |
| Hemoglobin (g/dl)                 | 13.04 ± 4.02 | 10.93 ± 2.53 | 0.049***  |
| Hematocrit (%)                    | 41.43 ± 13.56| 34.65 ± 8.81 | 0.059***  |
| RBC (x 10^6/mm^3)                 | 4.19 ± 0.92  | 4.18 ± 0.90  | 0.945***  |
| WBC (x 10^3 /mm^3)                | 14.50 (1.10–37.10) | 10.80 (0.01–127.80) | 0.014    |
| Neutrophil (%)                    | 61.00 (41.00–89.00) | 52.50 (3.00–89.00) | 0.008    |
| Lymphocyte (%)                    | 30.00 (6.00–54.00) | 41.00 (6.00–94.00) | 0.012    |
| Monocyte (%)                      | 4.00 (0–11.00) | 5.00 (1.00–25.00) | 0.028    |
| Eosinophil (%)                    | 0 (0–6.00)   | 1.00 (0–16.00) | 0.256    |

p-value determined by *Chi-square test, Fisher's Exact test, ***Independent samples t test and Mann-Whitney U test where appropriate
| Variable               | Dead                  | Recovered              | p-value |
|------------------------|-----------------------|------------------------|---------|
| Platelet (x 10^6/mm³)  | 2.55 (0.24–5.78)      | 2.84 (0.12–7.76)       | 0.374   |
| Serum creatinine (mg/dl)| 0.70 (0.45–2.27)      | 0.47 (0.03–5.72)       | **0.011**|
| Sodium (mmol/l)        | 142.47 ± 5.53         | 141.27 ± 5.58          | 0.402***|
| Potassium (mmol/l)     | 5.40 ± 0.90           | 4.41 ± 1.02            | < **0.001*****|
| Chloride (mmol/l)      | 104.44 ± 6.07         | 101.84 ± 13.52         | 0.436***|

p-value determined by *Chi-square test, Fisher's Exact test, **Independent samples t test and Mann-Whitney U test where appropriate

**Discussion:**

COVID-19 can affect any age. However, globally, the frequency and case fatality of COVID-19 is comparatively low in the pediatric group[23]. Although several studies reported exclusively on children, a few studies compared the demographic and clinical features across different age ranges[24, 25]. Our study presents a comparative analysis of patient characteristics in neonates, infants, and children in the pediatric age group. We also explored the factors affecting death among pediatric patients with COVID-19.

The median age of our participants was 18 months (1.5 years), and we obtained COVID-19-affected neonates aged as low as one day and children as high as 17 years. Nearly half of the participants were aged less than one year, which is higher than that found by Anwar et al. [26]. The median age of pediatric patients with COVID-19 varies from study to study based on the target population and method of selection. A systematic review on the pediatric group by Patel [24] found that the reported median age ranges from 1 to 11 years. The author also presents a composite mean age of 7.9 years with an age range between 1 day and 17 years, similar to our study. These findings demonstrate the SARS-CoV-2 virus's ability to infect anyone and children most likely got the virus from their infected parents or family members. This assumption is supported by studies among neonates which showed that half of the patients had infections from their infected mother, and one-third were admitted to the hospital [27].

Males were more common than females in our study, which corresponds to the findings of other studies [24]. We found this true for all age range. The higher affinity of SARS CoV-2 towards males than females might be explained by the fact that angiotensin-converting enzyme 2 (ACE2), the receptor for the virus, is expressed more in the former sex than in the latter along with other sex-based immunological and hormonal differences [28].

We found that more than 60 percent of pediatric patients had malnutrition irrespective of age group. This finding is important, as nutrition shows a reciprocal relationship with infection, and good nutritional status is associated with good immune function [29]. Additionally, more than half of them had at least one comorbidity, with the frequency being significantly higher among children and infants than among neonates. However, the overall proportion of comorbidities found in our study was higher than that found in other studies [24] and lower than that in those who needed neonatal intensive care unit admission[30]. Most of the comorbidities were probably coincident or concomitant findings in COVID-19 rather than precipitating factors. As the virus spreads via airborne respiratory droplets and mostly causes mild or asymptomatic disease in the pediatric population,
in most cases, it was a coincidental finding in children presenting with other diseases in the hospital. However, some of the diseases might be consequent of COVID-19 as well. We noted multisystem inflammatory syndrome in 3 children, which was previously established as a rare but severe complication of COVID-19 among children[31].

Fever was the most common presentation, followed by breathlessness, abdominal pain, cough, seizure, and vomiting, among others. Two previous studies conducted among children with COVID-19 in Bangladesh[26, 32] also noted fever, cough, breathlessness, abdominal pain, and vomiting among the most common presenting features. In a systematic review of individual participant data, Christopher et al[33] reported similar patterns of presentation. However, the proportion of individual symptoms varied among studies. SARS CoV-2 binds with ACE2, which is ubiquitous in the human body with high expression in the lungs, heart, ileum, kidney, and bladder[34]. Hence, despite its entry through the lung, it might produce symptoms involving multiple systems of the body. However, respiratory and gastrointestinal intestinal intestinal presentation is the most common mode of presentation of the disease. We found that neonates were relatively asymptomatic compared to infants and children. Gastrointestinal complaints such as abdominal pain and vomiting were more common among children, and respiratory complaints such as breathlessness and cough were more common among infants. Christopher et al[33] noted that children less than 7 years old tended to present with gastrointestinal complaints compared to older children. Our findings also conform to their results, as most of the child participants in our study were young with a median age of 64 months (5.33 years).

On laboratory investigations, we noted that children had significantly lower WBC counts than neonates and infants, with infants having significantly lower neutrophils and higher lymphocyte counts than children. However, laboratory data varied across pediatric participants based on the presence of various comorbidities and were mostly within the normal range for the participants. Similarly, Patel noted that the test results presented in various studies of COVID-19 children were mostly within the reference range used for that particular study[24]. Interestingly, this is contrary to expected lymphopenia, and an elevated neutrophil-to-lymphocyte ratio has emerged as a characteristic feature of severe COVID-19 [35], probably because of the predominantly milder form of the disease in children.

Out of 288 participants for whom the outcome was known, 20 (6.9%) pediatric patients with COVID-19 died. However, the case-fatality rate increased to 8.2% when referred patients were excluded. We found that age was associated with death in pediatric patients with COVID-19, while sex, nutritional status, and the presence of comorbidities did not show any association. The proportion of deaths was significantly higher among neonates than among infants and children. This rate is higher than that found by Ghosh et al[32] (1.4%) and Anwar et al[26] (4.1%). The low number of neonates among their studies might explain the difference. However, Trevisanuto et al[27] found zero case fatalities among 44 newborns with COVID-19. The provision of a well-equipped and adequate number of neonatal intensive care units (NICUs) is an important requirement for the appropriate management of these groups of patients. However, this is often not possible in developing countries because of a lack of adequate treatment facilities. This could explain the high mortality among neonates found in our study. Our analysis also revealed that certain investigation results were significantly different between dead and alive patients. However, this might have been influenced by the higher number of neonates dying instead of infants and children, as the physiology of neonates differs fundamentally from that of older children.
The current study was limited by the small sample size collected from a single center, lack of detection of quantitative RT-PCR, radiological investigations, and dynamic detection of inflammatory markers. However, our study provided important insights into similarities and differences in characteristics, presentation, and outcome of COVID-19 among neonates, infants, and children in the context of Bangladesh.

**Conclusion**

The study presents a detailed clinico-epidemiological pattern of COVID-19 among neonates, infants, and children. About one-third of the patients remain asymptomatic. Fever and abdominal pain were the most prominent manifestations among symptomatic patients. Slight variation in the symptoms and laboratory investigations exists. In comparison to others, neonates are more vulnerable than other pediatric groups.

**Declarations**

**Funding:** None

**Competing interest statement:** The author declares no competing interest.

**Consent to participate:** Informed written consent was ensured before participation of all subjects from the accompanying parents.

**Availability of data and material:** Data and material are available from the corresponding authors and could be shared based on reasonable request.

**Author contributions:**

The conception and design: PKS, KG, MK, AM, MJH  
Data acquisition and data collection: SA, MR, NA, NF, SAAA, MS, NN, SSA, SWR  
Data analysis was done by AM, MJH, and KG  
Interpretation of the result: PKS, KG, MK, AM, MJH, SA, MR, NA, NF, SAAA, MS, NN, SSA, SWR  
Project administration: PKS, KG, SA, MR, NA, NF, SAAA, MS, NN, SSA, SWR  
First draft of the manuscript: PKS, KG, MK, AM, MJH and NA  
Review of the draft: PKS, KG, MK, AM, MJH, SA, MR, NA, NF, SAAA, MS, NN, SSA, SWR  
Final approval: PKS, KG, and MJH

**Acknowledgment:**

The investigator team acknowledged the Department of Epidemiology & Research, Dhaka Shishu (Children) Hospital for their constant support for data collection and data analysis, Child Health Research Foundation,
Bangladesh for RT-PCR testing, and ‘Pi Research Consultancy Center’ (www.pircc.org) Bangladesh for their cordial support for manuscript formatting and journal selection.

References

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–33. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2001017
2. ICTV. International Committee on Taxonomy Viruses Naming the 2019 Coronavirus. 2020 [cited 2020 Oct 11]. Available from: https://talk.ictvonline.org
3. Kandel N, Chungong S, Omaar A, Xing J. Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries. Lancet (London, England). 2020;395(10229):1047–53.
4. Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52(4):583–9.
5. Barrero-Castillero A, Beam KS, Bernardini LB, et al. COVID-19: neonatal–perinatal perspectives. J Perinatol. 2020;2.
6. WHO. Coronavirus disease (COVID-19) pandemic. 2021. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
7. WHO. Coronavirus disease (COVID-19) update. 2021. Available from: https://www.who.int/bangladesh/emergencies/coronavirus-disease-(covid-19)-update
8. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708–20. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2002032
9. Wong CKH, Wong JYH, Tang EHM, et al. Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis. Sci Rep. 2020;10(1):1–16.
10. Hasan MJ, Tabssum T, Ambia NE, et al. Mental Health of the COVID-19 Patients in Bangladesh. Mymensingh Med J. 2021 Jan;30(1):189–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33397873
11. Ma H, Hu J, Tian J, et al. A single-center, retrospective study of COVID-19 features in children: a descriptive investigation. BMC Med. 2020 Dec 6;18(1):123. Available from: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01596-9
12. Wei M, Yuan J, Liu Y, et al. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA. 2020;13(323):1313. Available from: https://jamanetwork.com/journals/jama/fullarticle/2761659
13. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020 Apr 7;323(13):1239. Available from: https://jamanetwork.com/journals/jama/fullarticle/2762130
14. CDC COVID-19 Response Team. Coronavirus disease 2019 in children—United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;2020(69):422–6.
15. Guo CX, He L, Yin JY, et al. Epidemiological and clinical features of pediatric COVID-19. BMC Med. 2020;18(1):1–7.
16. Li B, Zhang S, Zhang R, et al. Epidemiological and Clinical Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis. Front Pediatr. 2020;8(November):1–12.

17. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 Apr 23;382(17):1663–5. Available from: http://www.nejm.org/doi/10.1056/NEJMc2005073

18. Viner RM, Ward JL, Hudson LD, et al. Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents. Arch Dis Child. 2020 Dec 17;archdischild-2020-320972. Available from: https://adc.bmj.com/lookup/doi/10.1136/archdischild-2020-320972

19. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr Int J Paediatr. 2020;109(6):1088–95.

20. Castagnoli R, Votto M, Licari A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents. JAMA Pediatr. 2020 Sep 1;174(9):882. Available from: https://jamanetwork.com/journals/jamapediatrics/fullarticle/2765169

21. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. 2020 [cited 2021 Apr 17]. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.

22. Foundation TI. Guidelines on clinical management of Thalassaemia. 2008;(November). Available from: http://www.thalassaemia.org.cy/

23. Worldometers.info. Age, Sex, Existing Conditions of COVID-19 Cases and Deaths. 2021.

24. Patel S. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information. Gene Reports. 2017;7(January):127–41.

25. Soares G, Barros G, Cordeiro KR, et al. Epidemiological characteristics of COVID-19 in pediatric patients under 10 years old: a systematic review Características epidemiológicas da COVID-19 em pacientes pediátricos menores de 10 anos: uma revisão sistemática. 2021;1(Suppl 2):39–40.

26. Anwar S, Shamsad IA, Morshed AKMA, et al. Clinical Profile of Child COVID-19 Patients of Bangladesh. 2021;7(March 2020):5–8.

27. Trevisanuto D, Cavallin F, Cavicchiolo ME, et al. Coronavirus infection in neonates: A systematic review. Arch Dis Child Fetal Neonatal Ed. 2020;1–6.

28. Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? SN Compr Clin Med. 2020;2(7):874–6.

29. Scrimshaw NS, SanGiovanni JP. Synergism of nutrition, infection, and immunity: An overview. Am J Clin Nutr. 1997;66(2).

30. Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. 2020;174(9):868–73.

31. Consiglio CR, Cotugno N, Sardh F, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183(4):968-981.e7. Available from: http://dx.doi.org/10.1016/j.cell.2020.09.016
32. Ghosh UK, Sultana A, Ghosh NK, et al. Clinico-demographic Profile of Coronavirus Infection among Bangladeshi Children: A Tertiary Care Hospital Study. Bangladesh J Infect Dis. 2020;7(October):S16–21.

33. Christophers B, Marin BG, Oliva R, et al. Trends in clinical presentation of children with COVID-19: a systematic review of individual participant data. Pediatr Res. 2020;(July). Available from: http://dx.doi.org/10.1038/s41390-020-01161-3

34. Yuki K, Fujiogi M, Koutsogiannaki S, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information. 2020; (January).

35. Reusch N, De Domenico E, Bonaguro L, et al. Neutrophils in COVID-19. Front Immunol. 2021;12(March):652470. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33841435%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC8027077

Figures

![Pie chart](image)

**Figure 1**

Outcome of pediatric patients with COVID-19 (n=288)
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- 1122.5.SupplementaryfileV13.docx